Full-Time

Head of AI Clinical Excellence

Updated on 8/23/2026

Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$176.6k - $294.3k/yr

+ 20% bonus target + Share-based long-term incentive program

No H1B Sponsorship

Cambridge, MA, USA + 4 more

More locations: Collegeville, PA, USA | Bothell, WA, USA | New York, NY, USA | San Diego, CA, USA

Hybrid

Hybrid role requiring commuting distance and an average of 2.5 days on-site per week. Occasional travel may be required.

Master's, PhD, MD

Category
Biology & Biotech (1)
Required Skills
LLM
Data Science
Machine Learning
Biostatistics
Risk Management

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • An MD and 4+ years of relevant experience within pharmaceutical, biotechnology, CRO, regulatory, or healthcare organizations; or a PhD in Life Sciences, Clinical Research, Data Science, Biostatistics, Computer Science, Engineering, or a related field and 5+ years of relevant experience; or an MS in those fields and 7+ years of relevant experience.
  • Experience designing, developing, and implementing artificial intelligence, machine learning, or advanced analytics solutions in clinical research settings.
  • Experience supporting Clinical Development, Clinical Operations, Clinical Science, Clinical Data Review, or Regulatory Science activities.
  • Experience leading cross-functional programs involving clinical, regulatory, scientific, and technical stakeholders.
  • Strong understanding of good clinical practice, clinical trial conduct, drug development processes, and regulatory requirements.
  • Experience translating complex scientific or operational challenges into scalable technology-enabled solutions.
  • Candidates must be authorized to be employed in the United States by any employer and have permanent work authorization in the United States.
Responsibilities
  • Develop and execute the enterprise strategy for artificial intelligence-enabled Clinical Excellence across Clinical Development.
  • Identify high-value opportunities to accelerate development timelines, improve quality, reduce operational burden, and enhance decision-making through artificial intelligence.
  • Serve as a trusted advisor to senior leaders on emerging artificial intelligence capabilities, industry trends, and competitive advancements.
  • Drive adoption of artificial intelligence solutions across study design, protocol optimization, feasibility assessments, patient recruitment, trial execution, and clinical data review.
  • Lead development of artificial intelligence-enabled approaches to improve clinical trial performance, operational excellence, and portfolio decision-making.
  • Enable predictive and prescriptive analytics to support program-level and study-level decisions.
  • Partner with digital, data science, and technology teams to design, build, validate, and deploy artificial intelligence-powered tools and platforms.
  • Establish frameworks for scalable artificial intelligence solutions that integrate into existing clinical development workflows.
  • Develop agentic artificial intelligence, generative artificial intelligence, predictive analytics, and workflow automation solutions supporting clinical operations and development teams.
  • Provide subject matter expertise on global regulatory expectations for artificial intelligence, machine learning, and advanced analytics within drug development.
  • Partner with Regulatory Affairs and Quality organizations to establish artificial intelligence governance frameworks, validation approaches, and risk management processes.
  • Monitor evolving health authority guidance and industry standards related to artificial intelligence-enabled development activities.
  • Build partnerships across Oncology Clinical Development, Clinical Operations, Biostatistics, Regulatory Affairs, Medical, Safety, and Digital organizations.
  • Lead multidisciplinary teams responsible for artificial intelligence innovation initiatives.
  • Drive organizational adoption through education, change management, and capability building.
  • Represent the organization in industry forums, consortiums, health authority interactions, and scientific conferences related to artificial intelligence and Clinical Development innovation.
  • Build relationships with external partners, technology providers, and academic collaborators.
Desired Qualifications
  • Expertise in Clinical Development, Oncology, Regulatory Science, Data Science, or Clinical Informatics.
  • Experience developing and deploying large language models, generative artificial intelligence, agentic artificial intelligence systems, or workflow automation platforms in regulated environments.
  • Experience in Oncology.
  • Familiarity with emerging regulatory frameworks governing artificial intelligence-enabled drug development.
  • Experience interacting with global regulatory agencies, including the FDA, EMA, MHRA, PMDA, and Health Canada.
  • Experience leading enterprise artificial intelligence transformation initiatives.
  • Strong publication record and scientific credibility within clinical research and artificial intelligence innovation.
  • Experience building and leading high-performing teams.
  • Ability to influence and collaborate with peers, develop and coach others, and oversee and guide colleagues' work to achieve meaningful outcomes and business impact.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Pfizer raised 2026 revenue guidance to $60.5-$62.5 billion on August 4, 2026.
  • Ex-COVID revenue grew 5% in Q2 2026, driven by Eliquis and Padcev.
  • FDA priority review for Talzenna-Xtandi targets a Q4 2026 approval decision.

What critics are saying

  • Eliquis loses U.S. exclusivity in 2028, threatening Pfizer’s biggest 2026 revenue engine.
  • Paxlovid fell 95% and Comirnaty dropped 34% in Pfizer’s second quarter 2026.
  • If Eliquis replacement and pipeline launches fail, Pfizer becomes a slow-decline cash distributor.

What makes Pfizer unique

  • Pfizer pairs Eliquis scale with oncology assets like Padcev and Talzenna in 2026.
  • Prevnar 20 won Québec public funding in May 2026, deepening vaccine franchise access.
  • Pfizer and Valneva’s Lyme vaccine moved into EMA review on August 14, 2026.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-4%
Yahoo Finance
Aug 19th, 2026
Intel CEO invests $10M in shares as chipmaker posts 25% revenue growth driven by AI demand

Intel CEO Lip-Bu Tan purchased nearly $10 million worth of shares as part of the chipmaker's recent stock offering, signalling confidence in the company's turnaround. Intel recently reported revenues of $16.1 billion, growing 25% year-over-year, with its Data Centre and AI business unit seeing revenue surge nearly 60% to $6.3 billion. CoStar Group founder and CEO Andrew Florance purchased 83,300 shares totalling roughly $2.5 million. Pfizer CEO Albert Bourla similarly invested, purchasing 38,000 shares for just over $1 million. These insider purchases reflect executives' confidence in their companies' longer-term outlook, with investors often viewing such moves as a positive signal.

Yahoo Finance
Aug 18th, 2026
Two profitable stocks with solid fundamentals and one to ignore

Two companies leverage profitability to outpace competitors, whilst another faces headwinds, according to StockStory's analysis. Primoris, which builds and maintains infrastructure in utility, energy, and civil construction sectors, struggles with a low gross margin of 10.3% reflecting high production costs. The company has seen falling earnings per share over two years and weak free cash flow margin of 2.2% over five years. BrightSpring Health Services, offering home health care and pharmacy services, has posted 23.9% annual revenue growth over two years. Its revenue base of $14.37 billion provides economies of scale. Pfizer's massive $63.7 billion revenue base gives it significant negotiating power. The pharmaceutical giant's adjusted operating margin expanded by 18.5 percentage points over two years, whilst delivering a 17.5% return on capital.

Yahoo Finance
Aug 11th, 2026
Pfizer raises 2026 guidance to $62.5B, but boost relies on Eliquis facing patent expiry

Pfizer reported second-quarter revenue of $15 billion, up 3% year over year, and raised its 2026 revenue guidance to between $60.5 billion and $62.5 billion. However, investors showed limited enthusiasm. The pharmaceutical giant's anticoagulant Eliquis, shared with Bristol Myers Squibb, generated $2.4 billion in quarterly revenue, up 21% year over year. The drug is now Pfizer's best-selling product. The concern is that Eliquis will lose patent exclusivity by the end of the decade. Pfizer's increased reliance on a drug facing imminent generic competition may signal it has yet to identify a suitable replacement. The company is expanding its pipeline, particularly in the GLP-1 market, where its candidate berobenatide is undergoing phase 3 trials after posting strong phase 2 results.

Yahoo Finance
Aug 11th, 2026
Pfizer raises guidance to $62.5B as BioNTech cuts forecast amid $928M loss

Pfizer and BioNTech reported contrasting second-quarter 2026 results as their post-pandemic strategies diverge. While the European Commission authorised their updated COVID-19 vaccine on 29 July, the former partners now face different financial realities. Pfizer posted revenues of $15 billion, up 1% operationally year-over-year. Excluding COVID products, revenue grew 5%, driven by strong performance from Eliquis, Padcev, and other non-COVID products. The company raised full-year revenue guidance by $500 million to $60.5–$62.5 billion and announced productivity initiatives expected to deliver $2.5 billion in additional savings between 2027 and 2029. BioNTech revenues fell 59.5% to €105.6 million as COVID vaccine demand declined. The company reported a net loss of €820.8 million and reduced full-year revenue guidance to €1.6–€1.9 billion. BioNTech maintains €16.6 billion in cash reserves.

Yahoo Finance
Aug 10th, 2026
Pfizer's earnings fall 58%, but dividend appears safe for now

Pfizer reported a 58% decline in net income for the first half of 2024, falling to $2.4 billion from $5.9 billion year-over-year. The decline was largely driven by $3.8 billion in non-cash impairment charges related to in-process research and development assets. Despite the earnings drop, the dividend appears sustainable. Over the past four quarters, Pfizer generated $11 billion in free cash flow, exceeding the approximately $9.8 billion paid in dividends. The company has struggled with growth whilst managing restructuring costs and integrating recent acquisitions. Its second quarter ended 30 June with a $248 million net loss. Pfizer's stock has fallen 44% over five years, though it's up 9% year-to-date. The dividend currently yields 6.4%.